Tags:BioTechDrug
Early stage biotech company focused on commercialization of dry-eye treatment, and orphan drug for systemic sclerosis.
Member count: 11-50

Investors 1

Mentions in press and media 1

DateTitleDescriptionCategoryAuthorSource
10.07.2007ArGentis P...ArGentis Pharmaceuticals, a Me...--venturebea...